Use of Dried Blood Spot to Improve the Diagnosis and Management of HIV in Resource-Limited Settings

Chatté Adawaye, Erick Kamangu, Ali Mahamat Moussa, Bertin Tchoumbou, Dolores Vaira, Michel Moutschen

.
Institute of Science and Technology of Abeche, Abeche, Chad.

DOI: 10.4236/wja.2013.33033                

Abstract

Over 75% of people infected with HIV live in countries where health resources are very limited for the diagnosis and biological monitoring of people infected by the virus. In resource-limited settings, the use of DBS is a valuable alternative. It has provided technical and economical alternative to the collection of blood in the tubes for testing HIV infection. The DBS can be kept for over a year, it is economical in storage space and facilitates storage conditions because it can be stored at room temperature. It is more discreet and easier to carry over liquid samples that require tubes and other appropriate materials. The amount is sufficient for certain analyses of DNA generally, but may be insufficient for the analysis of viral RNA if the viral load is low. Its disadvantage is often associated with small amounts of blood collected available for testing, and the difficulties encountered in laboratories to extract the maximum possibilities without material contamination. DBS can be stored at room temperature (25℃ - 35℃), at 4℃, -20℃ or even -70℃. With PCR, the DBS is a suitable medium for the diagnosis of patients infected with HIV, virological monitoring by the VL and even analyzing viral genotype. It is a handy stand for the collection, transport and analyses of biological monitoring of HIV infection. It is indeed very suitable for environments with limited accessibility where it is difficult for specialized laboratories to monitor these patients. The DBS is suitable for resource-limited settings.

Keywords

DBS; HIV; Resources Limited Setting; Viral Load; Genotyping

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	ONUSIDA-Organisation Mondiale de la Santé, “Rapport des données épidémiologiques,” 2012. www.unaids.org
[2]	J. W. Mellors, A. Munoz, J. V. Giorgi, J. B. Margolick, C. J. Tassoni, et al., “Plasma Viral Load and CD4+ Lymphocytes as Marker of HIV-1 Infection,” Annals of Internal Medicine, Vol. 126, No. 12, 1997, pp. 946-954. doi:10.7326/0003-4819-126-12-199706150-00003
[3]	A. Ammann and S. Burrowers, “Early Diagnosis of HIV Infection in HIV-Exposed Infants: Can Complexity and Cost Be Overcome in Resource-poor Settings? Women, Children, and HIV. Resources for Prevention and Treatment,” 2007. www.womenchildrenhiv.org
[4]	B. Ledergerber, J. D. Lundgren and A. S. Walker, “Predictors of Trend in CD4-Positive T-Cell Count and Mortality among HIV-1-Infected Individuals with Virological Failure to All Three Antiretroviral-Drug Classes,” Lancet, Vol. 364, No. 9428, 2004, pp. 51-62. doi:10.1016/S0140-6736(04)16589-6
[5]	A. Bahrani, R. Ramaswamy and E. C. Oldfield, “Effects of Virologic Rebound on CD4 Cell Counts,” Medicine Clinical Infectious Diseases, Vol. 32, No. 8, pp. 1231-1232. doi:10.1086/319755
[6]	N. E. Kamangu, M. E. Kawila, H. Mukumbi and L. G. Mvumbi, “Estimated Rates of Treatment Failure in First-Line Antiretroviral Treatment in Kinshasa: Case of ACS-AMO-Congo,” IJCRIMPH, Vol. 4, No. 6, 2012, pp. 885-891.
[7]	J. V. Mei, J. R. Alenxander, B. W. Adam and W. H. Hannon, “Use of Filter Paper for Collection and Analysis of Human Whole Blood Specimens,” Journal of Nutrition, Vol. 131, 2001, pp. 1631S-1636S.
[8]	A. Johannessen, C. Garrido, N. Zahonero, L. Sandvik, E. Naman, S. L. Kivuyo, et al., “Dried Blood Spots Perform Well in Viral Load Monitoring of Patients Who Received Antiretroviral Treatment in Rural Tanzania,” Medicine Clinical Infectious Diseases, Vol. 49, No. 6, 2009, pp. 976-981. doi:10.1086/605502
[9]	L. C. Ivers, M. C. Smith Fawzi, J. Mann, J. G Jerome, M. Raymonville and J. S. Mukherjee, “Overseas Processing of Dried Blood Spots for Timely Diagnosis of HIV in Haitian Infants,” The Pan American Journal of Public Health, Vol. 24, No. 5, 2008, pp. 331-335. doi:10.1590/S1020-49892008001100005
[10]	D. Anitha, P. Sumathi and S. MiniJacob, “Comparative of Venous Liquid Blood and Dried Blood for HIV Infection in Infants,” International Journal Of Biological and Medical Research, Vol. 3, No. 1, 2012, pp. 1369-1372.
[11]	I. Beck, K. D. Drenna, A. J. Melvin, et al., “Simple, Sensitive, and Specific Detection of Human Immunodeficiency Virus Type 1 subtype B DNA in Dried Blood Samples for Diagnosis in Infants in the Field,” Journal of Clinical Microbiology, Vol. 39, No. 1, 2001, pp. 29-33. doi:10.1128/JCM.39.1.29-33.2001
[12]	UNAIDS-WHO Working Group on Global HIV/AIDS/ STI Surveillance, “Guidelines for Using HIV Testing Technologies in Surveillance,” 2009.
[13]	J. C. Plantier, R. Dachraoui, V. Lemée, M. Gueudin, F. Borsa-Lebas, F. Caron and F. Simon, “HIV-1 Resistance Genotyping on Dried Serum Spots,” AIDS, Vol. 19, No. 4, 2005, pp. 391-397. doi:10.1097/01.aids.0000161768.98534.e7
[14]	F. Barin, L. L. Meyer, R. Lancar, C. Deveau, M. Gharib, A. Laporte, J. C. Desenclos and D. Costagliola, “Development and Validation of an Immunoassay for Identification of Recent Human Immunodeficiency Virus Type 1 Infections and Its Use on Dried Serum Spots,” Journal of Clinical Microbiology, Vol. 43, No. 9, 2005, pp. 4441-4447. doi:10.1128/JCM.43.9.4441-4447.2005
[15]	R. Dachraoui, D. Brand, S. Brunet, F. Barin and J. C. Plantier, “RNA Amplification of the HIV-1pol and Env Regions on Dried Serum and Plasma Spots,” HIV Medicine, Vol. 9, 2008, pp. 557-561. doi:10.1111/j.1468-1293.2008.00604.x
[16]	R. L. Hamers, P. W. Smit, W. Stevens, R. Schuurman and T. F. Rinke de Wit, “Dried Fluid Spots for HIV Type 1 Viral Load and Resistance Genotyping: A Systematic Review,” Antiviral Therapy, Vol. 14, 2009, pp. 619-629.
[17]	R. Dachraoui, A. Depatureaux, M. Chakroun, et al., “Monitoring of HIV-1 Resistance in Tunisia (North Africa) with a Dried Plasma Spots Strategy,” Journal of Acquired Immune Deficiency Syndromes, Vol. 47, No. 4, 2008, pp. 522-525. doi:10.1097/QAI.0b013e318166498a
[18]	M. Monleau, C. Montavon, C. Laurent, M. Segondy, B. Montes, E. Delaporte, F. Boillot and M. Peeters, “Evaluation of Different RNA Extraction Methods and Storage Conditions of Dried Plasma and Blood Spots for Human Immunodeficiency Virus Type 1 RNA Quantification and PCR Amplification for Drug Resistance Testing,” Journal of Clinical Microbiology, Vol. 47, No. 4, 2009, pp. 1107-1118. doi:10.1128/JCM.02255-08
[19]	M. Andreotti, M. Pirillo, G. Guidotti, S. Ceffa, G. Paturzo, P. Germano, R. Luhanga, D. Chimwaza, M. G. Mancini, M. C. Marazzi, S. Vella, L. Palombi and M. Giuliano, “Correlation between HIV-1 Viral Load Quantification in Plasma, Dried Blood Spots and Dried Plasma Spots Using the Roche COBAS TaqMan Assay,” Journal of Clinical Virology, Vol. 47, No. 1, 2010, pp. 4-7. doi:10.1016/j.jcv.2009.11.006
[20]	J. Dalmau, F. M. Codoner, I. Erkizia, M. Pino, C. Pou, R. Paredes, B. Clotet, J. Martinez-Picado and J. G. Prado, “In-Depth Characterization of Viral Isolates from Plasma and Cells Compared with Plasma Circulating Quasispecies in Early HIV-1 Infection,” PloS ONE, Vol. 7, No. 2, 2012, Article ID: e32714. doi:10.1371/journal.pone.0032714
[21]	S. Reigadas, M. H. Schrive, Aurillac-Lavignolle and H. J. Fleury, “Quantification of HIV-1 RNA in Dried Blood and Plasma Spots,” Journal of Virological Methods, Vol. 161, No. 1, 2009, pp. 177-180. doi:10.1016/j.jviromet.2009.06.002
[22]	S. Masciotra, C. Garrido, A. S. Youngpairoj, A. McNulty, N. ZZahonero, A. Corral, W. Heneine, C. de Mendoza and J. G. Garcia-Lerma, “High Concordance between HIV-1 Drug Resistance Genotypes Generayed from Plasma and Dried Blood Spots in Antiretroviral-Experienced Patients,” AIDS, Vol. 21, No. 18, 2007, pp. 2503-2511. doi:10.1097/QAD.0b013e3281c618db
[23]	A. J. Buckton, S. L. Bissett, R. E. Myers, et al., “Development and optimization of an internally controlled dried blood assay for surveillance of human immunodeficiency virus type 1 drug resistance,” Journal of Antimicrobial Chemotherapy, Vol. 62, No. 6, 2008, pp. 1191-1198. doi:10.1093/jac/dkn412
[24]	S. Uttayamakul, S. Likanonsakul, R. Sunthornkachit, et al., “Usage of Dried Blood Spots for Molecular Diagnosis and MonitoringHIV-1 Infection,” Journal of Virological Methods, Vol. 128, No. 1-2, 2005, pp. 128-134. doi:10.1016/j.jviromet.2005.04.010
[25]	J. Garcia-Lerma, A. McNulty, C. Jennings, D. Huang, W. Heneine and J. Bremer, “Rapid Decline in the Efficiency of HIV Drug Resistance Genotyping from Dried Blood Spots (DBS) and Dried Plasma Spots (DPS) Stored at 37℃ and High Humidity,” Journal of Antimicrobial Chemotherapy, Vol. 64, No. 1, 2009, pp. 33-36. doi:10.1093/jac/dkp150
[26]	S. Bertagnolio, L. Soto-Ramirez, R. Pilon, et al., “HIV-1 Drug Resistance Surveillance Using Dried Whole Blood Spots,” Antiviral Therapy, Vol. 12, 2007, pp. 107-113.
[27]	C. Wallis, C. Bell, P. Horsfield, T. Rinke de Wit and W. Stevens, “Affordable Resistance Test for Africa (ARTA): DBS Storage and Extraction Conditions for HIV Subtype C,” The 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention, Cape Town, 2009.
[28]	C. Ziemniak, A. George-Agwu, W. Moss, S. Ray and D. Persaud (2006) Sensitive Genotyping Assay for Detection of Drug Resistance Mutations in Reverse Transcriptase of HIV-1 Subtypes B and C in Samples Stored as Dried Blood Spots or Frozen ARN Extracts,” Journal of Virological Methods, Vol. 136, No. 1-2, 2006, pp. 238-247. doi:10.1016/j.jviromet.2006.05.030
[29]	J. Nelson, A. Loftis, D. Kamwendo, et al., “Nevirapine Resistance in Human Immunodeficiency Virus Type 1-Positive Infants Determined Using Dried Blood Spots Stored for Up to 6 Years at Room Temperature,” Journal of Clinical Microbiology, Vol. 447, No. 4, 2009, pp. 1209-1211. doi:10.1128/JCM.00254-09
[30]	A. Youngpairoj, S. Masciotra, C. Garrido, N. Zahonero, C. de Mendoza and J. Garcia-Lerma, “HIV-1 Drug Resistance Genotyping from Dried Blood Spots Stored for 1 Year at 4℃,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 6, 2008, pp. 1217-12120. doi:10.1093/jac/dkn100
[31]	A. McNulty, C. Jennings, D. Bennett, et al., “Evaluation of Dried Blood Spots for Human Immunodeficiency Virus Type 1 Drug Resistance Testing,” Journal of Clinical Microbiology, Vol. 45, No. 2, 2007, pp. 517-521. doi:10.1128/JCM.02016-06
[32]	A. Hearps, C. Ryan, L. Morris, M. Plate, V. Greengrass and S. Crowe, “Stability of Dried Blood Spots for HIV-1 Drug Resistance Analysis,” Current HIV Research, Vol. 8, No. 2, 2010, pp. 134-140. doi:10.2174/157016210790442740
[33]	N. Metha, S. Trzmielina, B. A. S. Nonyane, M. N. Eliot, R. Lin, A. S. Foulkes, K. McNeal, A. Ammann, V. Eulalievyolo, J. L. Suliman, K. Luzuriaga and M. Somasundaran, “Low-Cost HIV-1 Diagnosis and Quantification in Dried Blood Spots by Real Time PCR,” PLos ONE, Vol. 4, No. 6, 2009, Article ID: e5819. doi:10.1371/journal.pone.0005819
[34]	P. Mwaba, S. Cassol, A. Nunn, et al., “Whole Blood Versus Plasma Spots for Measurment of HIV-1 Viral Load in HIV-Infected African Patients,” Lancet, Vol. 362, No. 9401, 2003, pp. 2067-2068. doi:10.1016/S0140-6736(03)15103-3
[35]	S. S. Solomon, S. Solomon, I. Rodriguez, et al., “Dried Blood Spots (DBS): A Valuable Tool for HIV Surveillance in Developing/Tropical Countries,” International Journal of STD AIDS, Vol. 13, No. 1, 2002, pp. 25-28. doi:10.1258/0956462021924578
[36]	G. Somi, T. Kibuka, K. K. Diallo, et al., “Surveillance of Transmitted HIV Drug Resistance among Women Attending Antenatal Clinics in Dar es Salaam, Tanzania,” Antiviral Therapy, Vol. 13, Suppl. 2, 2008, pp. 77-82.
[37]	W. Stevens, L. Scott and S. Crowe, “Quantifying HIV for Monitoring Antiretroviral Therapy in Resource-Poor Settings,” The Journal of Infectious Diseases, Vol. 201, Suppl. 1, 2010, pp. S16-S26. doi:10.1086/650392
[38]	L. Waters, A. Kambungu, H. Tibenderana, et al., “Evaluation of Filter Paper Transfer of Whole-Blood and Plasma Samples for Quantifying HIV RNA in Subjects on Antiretroviral Therapy in Uganda,” Journal of Acquired Immune Deficiency Syndromes, Vol. 46, No. 5, 2007, pp. 590-593. doi:10.1097/QAI.0b013e318159d7f4
[39]	A. Mbida, S. Soso, P. Flori, et al., “Measure of Viral Load by Using the Abbott Real-Time HIV-1 Assay on Dried Blood and Plasma Spots Specimens Collected in 2 Rural Dispensaries in Cameroon,” Journal of Acquired Immune Deficiency Syndromes, Vol. 52, No. 1, 2009, pp. 9-16. doi:10.1097/QAI.0b013e3181aeccbc
[40]	K. Kamoto and J. Aberie-Grasse, “Surveillance of Transmitted HIV Drug Resistance with the World Health Threshold Survey Method in Lilongwe, Malawi,” Antiviral Therapy, Vol. 13, Suppl. 2, 2008, pp. 83-87.
[41]	J. Zhang, D. Kang, J. Fu, et al., “Surveillance of Transmitted HIV Type 1 Drug Resistance in Newly Diagnosed HIV Type 1 Infected Patients in Shandong Province, China,” AIDS Research and Human Retroviruses, Vol. 26, No. 1, 2010, pp. 99-103. doi:10.1089/aid.2009.0184
[42]	U. Neogi, S. Gupta, R. Rodridges, P. N. Sahoo, S. D. Rao, B. B. Rewari, S. Shastri, A. De Costa and A. Shet, “Dried Blood Spot HIV-1 RNA Quantification: A Useful Tool for Viral Load Monitoring among HIV-Infected Individuals in India,” The Indian Journal of Medical Research, Vol. 136, No. 6, 2012, pp. 956-962.
[43]	R. Hallack, L. Doherty, J. Wethers and M. Parker, “Evaluation of Dried Blood Spot Specimens for HIV-1 Drug-Resistance Testing Using the Trugene HIV-1 Genotyping Assay,” Journal of Clinical Virology, Vol. 41, No. 4, 2008, pp. 283-287. doi:10.1016/j.jcv.2007.12.011
[44]	M. T. Alvarez-Munoz, S. Zaragoza-Rodriguez, O. Rojas-Montes, et al., “High Correlation of Human Immunodeficiency Virus Type 1 Viral Load Measured in Dried-Blood Spot Samples and Plasma under Different Storage Conditions,” Archives of Medical Research, Vol. 36, No. 4, 2005, pp. 382-386. doi:10.1016/j.arcmed.2005.03.010
[45]	W. Ayele, R. Schuurman, T. Messele, et al., “Use of Dried Spots of Whole Blood, Plasma, and Mother’s Milk Collected on Filter Paper for Measurement of Human Immunodeficieny Virus type 1 Burden,” Journal of Clinical Microbiology, Vol. 45, No. 3, 2007, pp. 891-896. doi:10.1128/JCM.01919-06
[46]	C. T. Kane, H. D. Ndiaye, S. Diallo, et al., “Quantification of HIV-1 RNA in Dried Blood Spots by Real-Time NucliSENS EasyQ HIV-1 Assay in Senegal,” Journal of Virological Methods, Vol. 148, No. 1-2, 2008, pp. 291-295. doi:10.1016/j.jviromet.2007.11.011
[47]	B. Amellal, C. Katlama and V. Calvez, “Evaluation of the Use of Dried Spots and of Different Storage Conditions of Plasma for HIV-1 RNA Quantification,” HIV Medicine, Vol. 8, No. 6, 2007, pp. 396-400. doi:10.1111/j.1468-1293.2007.00484.x
[48]	M. C. Knuchel, Z. Tomasik, R. F. Speck, R. Luthy and J. Schupbach, “Ultrasensitive Quantitative HIV-1 p24 Antigen Assay Adapted to Dried Plasma Spots to Improve Treatment Monitoring in Low-Resource Setting,” Journal of Clinical Virology, Vol. 36, No. 1, 2006, pp. 64-67. doi:10.1016/j.jcv.2005.12.005
[49]	C. Garrido, N. Zahonero, D. Fernades, et al., “Subtype Variability, Virological Response and Drug Resistance Assessed on Dried Blood Spots Collected from HIV Patients on Antiretroviral Therapy in Angola,” Journal of Antimicrobial Chemotherapy, Vol. 61, No. 3, 2008, pp. 694-698. doi:10.1093/jac/dkm515
[50]	R. Lira, H. Valdez-Salazar, G. Vazquez-Rosales, et al., “Genotypic Testing for HIV-1 Drug Resistance Using Dried Blood Samples,” Archives of Virology, Vol. 155, No. 7, 2010, pp. 1117-1125. doi:10.1007/s00705-010-0696-y
[51]	X. Bi, H. Gatanaga, S. Ida, et al., “Emergence of Protease Inhibitor Resistance-Associated Mutations in Plasma HIV-1 Precedes that in Provirus of Peripheral Blood Mononuclear Cells by More than a Year,” Journal of Acquired Immune Deficiency Syndromes, Vol. 34, No. 1, 2003, pp. 1-6. doi:10.1097/00126334-200309010-00001
[52]	C. Chew, S. Potter, B. Wang, et al., “Assessment of Drug Resistance Mutations in Plasma and Peripheral Blood Mononuclear Cells at Different Plasma Viral Loads in Patients Receiving HAART,” Journal of Clinical Virology, Vol. 33, No. 3, 2005, pp. 206-216. doi:10.1016/j.jcv.2004.11.006
[53]	A. Johannessen, C. Garrido, N. Zahonero, et al., “HIV-1 Drug Resistance Testing from Dried Blood Spots Collected in Rural Tanzania Using the ViroSeq HIV-1 Genotyping System,” Journal of Antimicrobial Chemotherapy, Vol. 66, No. 2, 2011, pp. 260-264. doi:10.1093/jac/dkq433